Condition:   Sickle Cell Disease
Intervention:   Drug: Lexiscan
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Children's Hospital Boston;   Washington University School of Medicine;   LaJolla Institute for Allergy and Immunology;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified March 2010

Condition:   Fanconi Anemia
Interventions:   Drug: Chemotherapy Preparative Regimen;   Biological: Miltenyi CliniMACS
Sponsor:   Children's Hospital Medical Center, Cincinnati
Recruiting - verified March 2010

Condition:   Sickle Cell Disease
Interventions:   Drug: Propranolol;   Drug: Placebo
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2010

Conditions:   Iron Deficiency;   Anemia;   Kidney Disease
Interventions:   Drug: ferumoxytol;   Drug: iron sucrose
Sponsor:   AMAG Pharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Anemia
Intervention:  
Sponsor:   Hoffmann-La Roche
Not yet recruiting - verified March 2010

Conditions:   Pulmonary Hypertension;   Sickle Cell Disease;   Thalassemia
Interventions:   Drug: L-Glutamine;   Drug: L-Glutamine
Sponsor:   Children's Hospital & Research Center Oakland
Recruiting - verified February 2010

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Boceprevir (SCH 503034);   Drug: erythropoietin;   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908)
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Sickle Cell Disease
Interventions:   Other: High Demand / Low Infusion;   Other: PCA Dosing Plan
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Methemoglobinemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
Interventions:   Drug: chemotherapy;   Drug: dapsone;   Other: medical chart review;   Procedure: assessment of therapy complications
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Myelofibrosis;   Anemia, Aplastic;   Hemoglobinuria, Paroxysmal
Intervention:   Drug: Basiliximab
Sponsor:   Indiana University School of Medicine
Recruiting - verified March 2010

Conditions:   Anemia;   Chronic Kidney Disease
Interventions:   Drug: MK2578;   Drug: Comparator: MK2578;   Drug: Comparator: MK2578;   Drug: Comparator: darbepoetin alfa
Sponsor:   Merck
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
Interventions:   Biological: trivalent influenza vaccine;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Anemia
Intervention:   Drug: Epoetin alfa
Sponsors:   Stanford University;   National Institute on Aging (NIA)
Recruiting - verified February 2010

Conditions:   Sickle Cell Disease;   Secretory Phospholipase A2;   sPLA2
Interventions:   Biological: Single blood transfusion;   Behavioral: Standard care
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Viral Infection
Interventions:   Other: cytology specimen collection procedure;   Other: fluorescent antibody technique;   Procedure: assessment of therapy complications
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Pneumococcal Conjugate Vaccine
Intervention:   Biological: 13vPnC
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Chemotherapy Induced Anemia
Interventions:   Biological: Biological: ACE-011;   Drug: Placebo
Sponsors:   Acceleron Pharma, Inc.;   Celgene Corporation
Recruiting - verified March 2010

Condition:   Fanconi Anemia
Intervention:   Device: CliniMACs device
Sponsors:   Medical College of Wisconsin;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010

Conditions:   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation (TBI);   Device: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Sponsors:   Yale University;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified August 2008

Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2009

Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Kidney Disease;   Iron-Deficiency Anemia
Interventions:   Drug: IV Iron;   Drug: Ferrous Sulfate
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm
Interventions:   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: protein analysis;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: reduced-intensity transplant conditioning procedure;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Myelodysplastic Syndrome;   Aplastic Anemia
Interventions:   Drug: Thymoglobulin;   Drug: Cyclosporine;   Drug: Methylprednisolone;   Drug: G-CSF
Sponsors:   M.D. Anderson Cancer Center;   Genzyme
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Graft Versus Host Disease
Interventions:   Drug: Visilizumab;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Antithymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Institutes of Health (NIH)
Recruiting - verified March 2010

Conditions:   Thalassemia;   Iron Overload;   Hemochromatosis
Interventions:   Drug: Nifedipine;   Procedure: Phlebotomy;   Procedure: Urinalysis;   Procedure: Echocardiogram;   Procedure: Electrocardiogram
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2009

Conditions:   Beta Thalassemia Major;   Congenital Anemias
Intervention:   Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Sponsor:   Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010

Condition:   Anemia
Intervention:  
Sponsors:   Stanford University;   National Institute on Aging (NIA)
Recruiting - verified February 2010

Condition:   End-Stage Renal Disease
Intervention:   Other: Blood draw
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Louisville
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: alemtuzumab;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chuvash Polycythemia;   Cerebrovascular Disease;   Pulmonary Hypertension;   Sickle Cell Anemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010

Condition:   Sickle Cell Disease
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Anemia
Intervention:   Drug: Deferasirox
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: sargramostim;   Drug: entinostat;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Anemia;   Chronic Kidney Disease;   Kidney Disease
Interventions:   Drug: darbepoetin alfa QW;   Drug: darbepoetin alfa Q2W
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Secondary Myelofibrosis
Interventions:   Biological: filgrastim;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   The Canadian Blood and Marrow Transplant Group;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: sargramostim;   Drug: bexarotene;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis
Interventions:   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: CD4+CD25+ regulatory T cells;   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified September 2009

Condition:   Iron Overload
Intervention:   Drug: deferiprone
Sponsors:   Children's Hospital of Philadelphia;   ApoPharma
Available - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unusual Cancers of Childhood
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2007

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsor:   James P. Wilmot Cancer Center
Recruiting - verified June 2007

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Hemoglobinopathies;   Hemolysis;   Iron Deficiency and Overload;   Anemias
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: peripheral blood stem cell transplantation
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: sirolimus
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified November 2007

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Drug: methylprednisolone
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis;   Genetic: gene expression analysis;   Other: immunologic technique;   Other: flow cytometry;   Genetic: polymerase chain reaction;   Genetic: cytogenetic analysis;   Other: staining method
Sponsor:   Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010

Conditions:   Healthy;   Sickle Cell Anemia
Intervention:  
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009